The Bill & Melinda Gates Foundation recently donated $10 million to help support the creation of more effective therapeutics and vaccines.
Liquidia Technologies announced that they had received the donation following its recent clinical trial of its lead seasonal flu candidate (LIQ001) and an agreement with the PATH Malaria Vaccine Initiative. The leadership of Liquidia said that it was humbled by the generous gift and that it would help provide medication to those in need.
"We are delighted the Gates Foundation has decided to join an outstanding group of investors that share our confidence in the potential of PRINT technology to improve vaccine delivery and effectiveness," said Neal Fowler, chief executive officer at Liquidia. "As the field of vaccines continues to grow, success will be defined by our ability to produce and deliver highly efficacious therapies in quantities and costs that will support the global demand."
The Gates Foundation has been making headlines for a variety of different charitable efforts. The charity announced that it would be donating $20 million to the BBC World Service Trust to help increase public education around the world, the Seattle Times reported.